Nantahala Capital Management LLC Sells 6,909 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

Nantahala Capital Management LLC lowered its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 1.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 593,091 shares of the company’s stock after selling 6,909 shares during the quarter. Nantahala Capital Management LLC’s holdings in Eyepoint Pharmaceuticals were worth $3,215,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of EYPT. Wells Fargo & Company MN boosted its position in Eyepoint Pharmaceuticals by 78.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,792 shares of the company’s stock worth $259,000 after purchasing an additional 15,290 shares during the last quarter. Invesco Ltd. boosted its position in Eyepoint Pharmaceuticals by 16.1% in the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company’s stock worth $117,000 after purchasing an additional 2,177 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Eyepoint Pharmaceuticals in the fourth quarter worth $76,000. MetLife Investment Management LLC boosted its position in Eyepoint Pharmaceuticals by 38.3% in the fourth quarter. MetLife Investment Management LLC now owns 40,502 shares of the company’s stock worth $302,000 after purchasing an additional 11,217 shares during the last quarter. Finally, Voya Investment Management LLC boosted its position in Eyepoint Pharmaceuticals by 342.4% in the fourth quarter. Voya Investment Management LLC now owns 73,914 shares of the company’s stock worth $551,000 after purchasing an additional 57,205 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT stock opened at $11.57 on Monday. The company’s fifty day simple moving average is $10.45 and its two-hundred day simple moving average is $7.87. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $13.98. The stock has a market capitalization of $797.52 million, a price-to-earnings ratio of -4.32 and a beta of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The business had revenue of $5.33 million for the quarter, compared to the consensus estimate of $6.82 million. Equities research analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. HC Wainwright boosted their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Chardan Capital reiterated a “buy” rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Mizuho dropped their price objective on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, May 16th. Finally, Royal Bank Of Canada started coverage on Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They issued an “outperform” rating and a $28.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Eyepoint Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $26.86.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.